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Objective To assess whether vaginal secretions and breast milk of
women with coronavirus disease 2019 (COVID-19) contain severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Design Single centre cohort study.
Setting Renmin Hospital of Wuhan University, Wuhan, Hubei
province, China.
Population We studied 13 SARS-CoV-2-infected pregnant women
diagnosed between 31 January and 9 March 2020.
Methods We collected clinical data, vaginal secretions, stool
specimens and breast milk from SARS-CoV-2-infected women
during different stages of pregnancy and collected neonatal throat
and anal swabs.
Main outcomes and measures We assessed viral presence in
different biosamples.
Results Of the 13 women with COVID-19, five were in their first
trimester, three in their second trimester and five in their third
trimester. Of the five women in their third trimester who gave
birth, all delivered live newborns. Among these five deliveries, the
primary adverse perinatal outcomes included premature delivery
(n = 2) and neonatal pneumonia (n = 2). One of nine stool
samples was positive; all 13 vaginal secretion samples, and five
throat swabs and four anal swabs collected from neonates, were
negative for the novel coronavirus. However, one of three samples
of breast milk was positive by viral nucleic acid testing.
Conclusions In this case series of 13 pregnant women with
COVID-19, we observed negative viral test results in vaginal
secretion specimens, suggesting that a vaginal delivery may be a
safe delivery option. However, additional research is urgently
needed to examine breast milk and the potential risk for viral
contamination.
Keywords Breast milk, coronavirus disease 2019, vaginal
secretions.
Tweetable abstract New evidence for the safety of vaginal delivery
and breastfeeding in pregnant women infected with SARS-CoV-2,
positive viral result in a breast-milk sample.
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In December of 2019, Wuhan, in Hubei Province, China,
experienced an outbreak of pneumonia caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
On 11 March the World Health Organization declared that
the spread of coronavirus disease 2019 (COVID-19) was a
pandemic, which is now disrupting health and public life
around the world.1
SARS-CoV-2 shares 79% nucleotide sequence identity
with SARS-CoV and 50% with Middle-East respiratory syn-
drome coronavirus (MERS-CoV).2 Previous studies have
suggested that SARS-CoV infection during pregnancy may
carry severe complications including maternal death, spon-
taneous miscarriage, preterm delivery and intrauterine
growth restriction;3 and MERS has been associated with
intrauterine fetal demise and stillbirth.4,5
Human transmission is through droplets and direct con-
tact, though recent investigations have demonstrated that
SARS-CoV-2 is also detectable in stool and blood.6 No evi-
dence of vertical transmission was demonstrated in nine
pregnant women, and amniotic fluid, cord blood and
breast milk samples of six women were all negative.7 How-
ever, one newborn was diagnosed with SARS-CoV-2 infec-
tion within 36 hours of delivery, which raised the concern
of vertical transmission.8 Viral analysis of the vaginal
mucosa or secretions has not been reported, so there may
be a clinical tendency to promote caesarean delivery to
avoid intrapartum transmission.7 Furthermore, data on
breastfeeding are scarce and no one has examined the effect
of COVID-19 in the first and second trimesters of preg-
nancy. In view of these clinical gaps, we performed the ret-
rospective study.
Methods
All pregnant women with SARS-CoV-2 admitted to Ren-
min Hospital of Wuhan University in China between
31 January and 9 March 2020, and their babies admitted to
Wuhan Children’s Hospital (Wuhan Maternal and Child
Healthcare Hospital), Tongji Medical College, Huazhong
University of Science & Technology, were included. The
diagnostic criteria for COVID-19 were based on the Diag-
nosis and Treatment Protocol for the 2019 Novel Coron-
avirus Pneumonia published by the National Health
Commission of China.9 All patients were diagnosed
through real-time reverse transcription–polymerase chain
reaction assays of throat swab samples. This study was
approved by the Medical Ethical Committee of Renmin
Hospital of Wuhan University (No. WDRY2020-K097),
Wuhan Children’s Hospital (Wuhan Maternal and Child
Healthcare Hospital), Tongji Medical College, Huazhong
University of Science & Technology (No. WHCH 2020014)
and the International Peace Maternity and Child Health
Hospital, School of Medicine, Shanghai Jiao Tong Univer-
sity (No. GKLW2020-05).
We extracted demographic information, clinical course,
laboratory indices and imaging results of infected pregnant
women from the medical records, maternal throat swabs
were collected upon admission. Samples of vaginal secre-
tions from nine women were collected during pregnancy
and samples from four women were collected after delivery.
Neonatal throat and anal swabs were collected on the 1st
and 3rd days after birth. Breast milk samples from three
women were collected on the 1st, 6th and 27th days after
delivery and stool specimens were taken from nine women
between 5 and 8 March. The details of sample collection are
shown in the Supplementary material (Tables S1 and S2).
We collected throat swabs, anal swabs, vaginal secretions
and stool specimens using sterile polyester swabs. After col-
lection, samples were placed in sterile tubes and transported
to the laboratory at 4°C. For breast-milk collection, iodine
was used to disinfect the patient’s breast. Breast milk was
expressed into a sterile container. Maternal samples were
processed at the Laboratory of Renmin Hospital of Wuhan
University, and neonatal samples were processed at the Lab-
oratory of Wuhan Children’s Hospital. Both laboratories
met the World Health Organization standard.10
Results
We reviewed the medical records of 13 pregnant women
with SARS-CoV-2 infection; where five were infected in the
first trimester, three in the second trimester and five in the
third trimester. One of the infants included here has been
previously reported.11 All women had a history of viral
exposure in the central epidemic area in and around
Wuhan. The women were between 26 and 40 years of age,
with parity ranging from 0 to 2; hospital admission for
infection occurred between 5 and 38 weeks of gestation. All
women were diagnosed as having mild COVID-19 without
severe complications, and none was admitted to the inten-
sive care unit. All women were provided with oxygen sup-
port, antiviral therapy assisted by antibacterial treatment
was administered to eight women, and corticosteroid treat-
ment was given to three women. All 13 women are cur-
rently virus free (see Supplementary material, Table S3).
In terms of clinical manifestations, fever was the most
common symptom (n = 8); followed by cough (n = 5),
dyspnoea (n = 1), myalgia (n = 1) and diarrhoea (n = 1).
Three women demonstrated an increased leucocyte count,
two women had lymphopenia and five women had ele-
vated C-reactive protein levels. Impaired liver function
was observed in three women (with elevated levels of ala-
nine aminotransferase), and two women had increased
aspartate aminotransferase levels. Eight women manifested
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patchy ground-glass opacities or consolidation shadows,
with peripherally distributed computed tomography imag-
ing features.
Perinatal outcomes
In the five women in the first trimester of pregnancy, one
(patient 12) had a biochemical pregnancy with serum
human chorionic gonadotrophin concentrations dropping
from 25.9 IU/l to <2 IU/l. The other four women (patients
7, 9, 10 and 13) had ongoing pregnancies. All five women
in their third trimester (patients 1–5) delivered, with only
one (patient 5) undergoing vaginal birth. While patient 1
experienced dyspnoea – with fetal heart rate monitoring
that suggested fetal distress – the other three women exhib-
ited no clear medical indication for a caesarean section.
Lack of knowledge regarding COVID-19 and concerns
about potential mother-to-child transmission as a ‘social
factor’ became an indication for caesarean section in these
last three pregnant women (Table 1). The gestational age at
delivery ranged from 35+5 to 38+4 weeks. Two neonates
(babies of patients 1 and 2) were born prematurely (at 35+5
and 35+6 weeks), with birthweights of 2830 g and 2300 g,
respectively. The pregnancy of patient 1 was ended prema-
turely because of fetal distress, and patient 2 underwent a
spontaneous preterm birth. The neonate of patient 5 was
large for gestational age (at 3910 g) (see Supplementary
material, Table S4). Two of the five women had increased
leucocyte counts, and three of the five women continued to
show elevated C-reactive protein levels after delivery
(Table 1).
All five women delivered a live newborn; the infant of
patient 3 had a 1-min Apgar score of 7 and 5-min Apgar
score of 9, but the other four infants had normal Apgar
scores. Two neonates (babies of patient 1 and patient 2)
were born prematurely and diagnosed with neonatal pneu-
monia by chest X-ray (see Supplementary material, Fig-
ure S1). SARS-CoV-2 nucleic acid tests of neonatal throat
and anal swabs were all negative on the 1st and 3rd days
after birth.
Viral nucleic acid test results of vaginal secretions
and breast milk
All 13 vaginal secretions samples were negative for viral
nucleic acids and only one stool sample was positive (pa-
tient 12) (see Supplementary material, Table S3); the viral
nucleic acid tests of throat swabs of ten women were posi-
tive on the day of vaginal secretion collection (see Supple-
mentary material, Table S1). We assessed breast milk in
three women; the breast-milk sample of one woman (pa-
tient 5), collected on the 1st day after delivery, was positive
using the real-time reverse transcription–polymerase chain
reaction test for the open reading frame 1ab of SARS-CoV-
2 (see Supplementary material, Table S3), but subsequent
re-examination on the 3rd day after delivery was negative.
The other breast-milk samples, collected on the 6th and
27th days after delivery, were negative for the virus (see
Table 1. Childbirth characteristics
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 n (%)
Gestational age at delivery 35+6 weeks 35+5 weeks 38+4 weeks 37+6 weeks 38+2 weeks –
Onset to delivery (days) 11 0 NK 25 0 –











Indication for caesarean section Fetal distress Social factor* Social factor Social factor NA –
Laboratory characteristics (after delivery)
White blood cell count (9109 cells/l) 7.06 8.41 8.25 11.18 29.53 –
Low or normal leucocyte count (<9.5 9 109
cells/l)
Yes Yes Yes No No 3
(60%)
Lymphocyte count (9109 cells/l) 1.72 1.07 2.06 1.28 0.58 –
Lymphopenia (<109 cells/l) No No No No Yes 1
(20%)
C-reactive protein concentration (mg/l) 29.1 64.0 8.7 87.6 ND –
Elevated C-reactive protein (>10 mg/l) Yes Yes No Yes NA –
Intraoperative blood loss (ml) 200 ml 200 ml 200 ml 300 ml NA –
2 hours postpartum bleeding (ml) 300 ml 300 ml 300 ml 300 ml 100 ml –
Detection of SARS-CoV-2 in breast milk Negative ND ND Negative Positive –
NA, not applicable; ND, not done; NK, not known.
*Social factor: these women had no medical indication for caesarean section, and the patient’s choice of caesarean section was attributed to
social reasons in the medical records.
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Supplementary material, Table S1). The viral-detection
results for all participants are summarised in Figure 1.
Data from neonate 4, born in Renmin Hospital, sug-
gested no diagnosis of SARS-CoV-2 infection; this newborn
had four negative swabs, no clinical symptoms or signs and
received no treatment. However, the newborn was subse-
quently found to have IgM and IgG seroconversion. This
newborn has been previously reported elsewhere.11
Discussion
Main findings
In this study, the clinical characteristics of the pregnant
women were mild compared with the general Chinese pop-
ulation, and none of them progressed to severe pneumo-
nia.12 SARS-CoV-2 was not found in the 13 vaginal swabs,
and none of the five newborns was infected, although one
of the three breast-milk samples was positive for the virus.
Strengths and limitations
Our study is the first to report on 13 women at various
stages of pregnancy with laboratory-confirmed SARS-CoV-
2 infection, and on the ensuing safety of a vaginal birth
and breastfeeding. Our study has some limitations. First,
only 13 pregnant women with SARS-CoV-2 infection and
five newborns were included in our study; therefore, addi-
tional studies with larger sample sizes are required to con-
firm our preliminary results. Furthermore, there were no
pregnant women with severe symptoms requiring intensive
care in our study, limiting the clinical implications. Also,
all women in our study were from the Renmin Hospital of
Wuhan University, so it is not known if our results are
Figure 1. Summary of virus detection in pregnant women with COVID-19. Samples of vaginal secretions, breast milk and stool were collected from
13 pregnant women with SARS-CoV-2 infection. Four of the pregnant women in their third trimester (Patients 1 to 4) had caesarean sections, one
woman (patient 5) had a vaginal birth. The neonatal throat and anal swabs were collected on the 1st and 3rd days after birth to detect the COVID-
19 virus. Four neonates received chest X-rays or computed tomography imaging on the 2nd day after birth.
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applicable to other medical centres. Given the widespread
nature of this global public health emergency, there may be
different clinical characteristics in different COVID-19-
epidemic areas due to differences in race, culture, policies
and medical conditions. Further studies involving addi-
tional populations and multiple centres are required to
confirm our results. Finally, this was a retrospective study,
which limited our ability to examine the long-term health
effects on infants born to mothers with COVID-19.
Interpretation
Vertical transmission is a key concern for pregnant women
with SARS-CoV-2 infection. None of the newborns deliv-
ered in our study was infected, a result consistent with pre-
vious reports (e.g. negative tests for the novel coronavirus
nucleic acid in pharyngeal swab samples from 19 neonates
born to mothers with COVID-19 pneumonia, and for three
placental samples13,14). Two newborns with neonatal coron-
avirus pneumonia were confirmed in Wuhan8,15 as of
5 February 2020; one of them was diagnosed with SARS-
CoV-2 infection 36 hours after birth. Expert clinical opin-
ion suggests that this SARS-CoV-2 infection was the result
of close contact with an infected individual rather than to
vertical transmission. In our study, one woman gave birth
vaginally and the newborn’s viral nucleic acid test was neg-
ative. However, it is unclear whether intrauterine transmis-
sion of SARS-CoV-2 occurs, and additional research is
therefore warranted.
Intrapartum transmission is another concern that may
affect mode of delivery. Many types of viruses – including
herpes simplex virus, human papillomavirus and
HIV – can be spread to neonates by intrapartum transmis-
sion.16–18 An important mechanism for viral intrapartum
transmission is through swallowing of infected vaginal
secretions during vaginal delivery. In this study, three of
four caesarean sections were performed without any medi-
cal indications in an attempt to avoid potential intra-
partum transmission. Importantly, we collected vaginal
secretions from the 13 women for viral nucleic acid testing
to clarify whether SARS-CoV-2 could be transmitted via
vaginal delivery; and our test results were negative in amni-
otic fluids and placentae from nine women, which should
reassure women who wish to deliver vaginally and can do
so.7,14 The results of our study support the recommenda-
tion that all infected pregnant women with COVID-19 who
do not have a medical indication for a caesarean section
should have a vaginal delivery.19
Some pathogens – such as herpes simplex virus and
Chlamydia trachomatis – can travel along the genital tract
and spread to the uterus, causing adverse neonatal out-
comes such as stillbirth and premature birth.20–22 Our neg-
ative results of vaginal secretions from 13 women, however,
suggest that ascending infection in COVID-19 was low. An
important mechanism underlying the entry of SARS-CoV-2
into human cells has been demonstrated through the interac-
tion between viral S-protein and angiotensin-converting
enzyme 2 (ACE2) in the host.2,23 Therefore, the distribution
of ACE2 expression may be closely associated with target-
organ damage and viral transmission. Although RNA and
protein expression levels for ACE2 are very low in the vagina,
uterus and cervix, the ACE2 receptor is expressed in the
digestive tract and oral mucosa.24,25 This may explain why
SARS-CoV-2 can be found in human saliva and faeces rather
than in vaginal secretions. While we could not find evidence
for intrapartum transmission of SARS-CoV-2, a previous
case report from our series indicated intrauterine serocon-
version of a neonate. This neonate showed no signs of sick-
ness after birth. Seroconversion was found only in this
pregnancy.11
Advice regarding breastfeeding is clearly a matter of con-
cern. Previous studies have found that HIV and hepatitis B
virus appear in breast milk and cause mother-to-infant
transmission;26,27 and that mothers with COVID-19 can
transmit the virus through respiratory droplets or skin con-
tact during breastfeeding. In contrast to a study that did not
find SARS-CoV-2 in the breast milk of women with COVID-
19,7 we found a positive viral nucleic acid test in one breast-
milk sample. Although we retested the breast milk from this
infected women 2 days later and found it to be negative, the
possibility of viral transmission through breast milk cannot
be excluded. Until large studies have demonstrated the safety
of breast milk, our advice is against the use of breastfeeding
even through breast expression; mothers with COVID-19
should not breastfeed until after full recovery, when breast
milk tests negative for the virus.
Our study confirms that pregnant women with SARS-
CoV-2 are not at high risk of severe illness and adverse
pregnancy outcomes, which is in accordance with previous
studies.7,28 Previous studies have shown that pregnant
women with SARS are prone to adverse maternal and
neonatal complications, including miscarriage, preterm
birth, intrauterine growth restriction, use of intubation and
admission to the intensive care unit, and have a mortality
rate of 25%.29 In the present study, pregnant women with
COVID-19, in contradistinction, exhibited far fewer adverse
maternal and neonatal complications and outcomes. One
reason for the discrepancy may be that SARS-CoV has a
significantly greater virulence than SARS-CoV-2, causing
SARS-CoV-infected patients to generally manifest more
severe signs and symptoms than SARS-CoV-2-infected
patients; and pregnant women have a poor prognosis when
suffering from severe pneumonia.
We also observed one pregnancy failure, raising concerns
that SARS-CoV-2 infection may induce early pregnancy
loss. The aetiology of a biochemical pregnancy is diverse
and may be the result of thrombophilic disorders,
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chromosomal anomalies, various endocrine disturbances,
immune dysfunction or disrupted endometrium.30 In addi-
tion, infection is a major cause of miscarriage; overall, 15%
of early miscarriages and 66% of late miscarriages are
related to infections.31 The association between a systemic
infection such as malaria, dengue fever, brucellosis, cytome-
galovirus, HIV, influenza or bacterial vaginosis, and an
increased risk of miscarriage has been well documented.31
The mechanisms of termination of pregnancy caused by
the influenza virus, SARS CoV or MERS CoV comprise
maternal respiratory difficulties and insufficient delivery of
oxygen to the embryo, and are not due to direct viral
infection of the fetus.2,3,32 The woman in our study who
experienced the biochemical pregnancy did not experience
dyspnoea, so fetal oxygenation was probably sufficient. It is
unclear whether the biochemical pregnancy was associated
with maternal infection, and therefore additional research
is warranted.
Conclusion
In summary, in our study we found no evidence for verti-
cal or intrapartum transmission of the novel coronavirus,
with negative test results for all of our vaginal samples.
One infected women gave birth vaginally to a healthy new-
born, providing additional evidence that a vaginal delivery
among infected women is a safe option. However, SARS-
CoV-2 could potentially be transmitted through breast
milk, and therefore further research is urgently needed. The
impact of SARS-CoV-2 infection on embryo health during
the first trimester of pregnancy also requires further inves-
tigation. With the global outbreak of COVID-19, we believe
that our findings provide health professionals with impor-
tant clinical information when treating infected pregnant
women and providing perinatal care.
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